MENU

BAX Stock Baxter International (BAX, $24.49) was a top loser this quarter, falling -19.46%

A.I.dvisor
at Tickeron.com
Loading...
BAX - Baxter International
Tickeron

Loading...

Price: $24.49
Daily change: +$0.51 (+2.13%)
Daily volume: 4M
3-month price change: -$5.92 (-19.46%)
Capitalization: $12.6B
Industry: Pharmaceuticals: Other
Baxter International (BAX, $24.49) was a top loser over the last three months, falling -1 to $24.49 per share. A.I.dvisor analyzed 107 stocks in the Pharmaceuticals: Other Industry for the 3-month period ending September 11, 2025, and found that of them () exhibited an Uptrend while of them () demonstrated a Downtrend.

BAX saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for BAX moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 47 similar instances where the indicator exited the overbought zone. In of the 47 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BAX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BAX's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BAX just turned positive on August 14, 2025. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 181 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.683) is normal, around the industry mean (11.051). P/E Ratio (87.846) is within average values for comparable stocks, (57.884). Projected Growth (PEG Ratio) (1.997) is also within normal values, averaging (1.748). Dividend Yield (0.028) settles around the average of (0.016) among similar stocks. P/S Ratio (1.128) is also within normal values, averaging (17.078).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
BAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BAX showed earnings on July 31, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
One Baxter Parkway
Phone
+1 224 948-2000
Employees
60000
Web
https://www.baxter.com